Sarcomas With Spindle Cell Morphology

Seminars in Oncology

Volumn 36, Issue 4, 2009, Pages 324-337

  Collini, Paola ^a   Sorensen, Poul H B ^b   Patel, Shreyaskumar ^c   Blay, Jean Yves ^d   Issels, Rolf D ^e   Maki, Robert G ^f   Eriksson, Mikael ^g   del Muro, Xavier Garcia ^h  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d EDOUARD HERRIOT HOSPITAL   (France)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^f MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^g LUND UNIVERSITY HOSPITAL   (Sweden)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CAMPTOTHECIN DERIVATIVE; DACARBAZINE; DEFOROLIMUS; DNA TOPOISOMERASE INHIBITOR; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; IMATINIB; MESNA; PACLITAXEL; PAZOPANIB; SORAFENIB; SULINDAC; SUNITINIB; TAMOXIFEN; TEMOZOLOMIDE; TOPOTECAN; TRABECTEDIN; VINCRISTINE;

ANGIOSARCOMA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER RADIOTHERAPY; CANCER RESEARCH; CANCER RISK; CANCER SURVIVAL; CELL STRUCTURE; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL TRIAL; CONTINUOUS INFUSION; DERMATOFIBROMA; DRUG EFFICACY; DRUG INHIBITION; DRUG MEGADOSE; EWING SARCOMA; FIBROSARCOMA; FUSION GENE; GASTROINTESTINAL STROMAL TUMOR; HEAT SHOCK RESPONSE; HEMANGIOPERICYTOMA; HISTOPATHOLOGY; HUMAN; HYPERTHERMIA; IMMUNOHISTOCHEMISTRY; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LIVER CELL CARCINOMA; MALIGNANT FIBROUS HISTIOCYTOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SARCOMA; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; SPINDLE CELL; SPINDLE CELL SARCOMA; SYNOVIAL SARCOMA;

CHEMOTHERAPY, ADJUVANT; FIBROSARCOMA; GENE FUSION; HEAT-SHOCK RESPONSE; HUMANS; HYPERTHERMIA, INDUCED; PROTEIN KINASE INHIBITORS; SARCOMA; SARCOMA, SYNOVIAL; TRANSLOCATION, GENETIC;

EID: 67949096046     PISSN: 00937754     EISSN: None     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2009.06.007     Document Type: Article

References (62)

1. Fletcher C.D.M., Unni K.K., Mertens F., and World Health Organization classification of tumours. Pathology and genetics of tumours of soft tissue and bone (2002), IARC Press, Lyon, France p. 427
2. Kempson R.L., Fletcher C.D.M., Evans H.L., Hendrickson M.R., and Sibley R.K. Atlas of tumor pathology: tumors of soft tissue (2001), Armed Forces Institute of Pathology, Washington, DC
3. Weiss S.W., and Goldblum J.R. Soft tissue tumors. 5th ed. (2008), Mosby-Elsevier, Philadelphia p. 1258
4. McArthur G.A., Demetri G.D., van Oosterom A., Heinrich M.C., Debiec-Rychter M., Corless C.L., et al. Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225. J Clin Oncol 23 (2005) 866-873
5. Maki R.G., Awan R.A., Dixon R.H., Jhanwar S., and Antonescu C.R. Differential sensitivity to imatinib of 2 patients with metastatic sarcoma arising from dermatofibrosarcoma protuberans. Int J Cancer 100 (2002) 623-626
6. Rubin B.P., Schuetze S.M., Eary J.F., Norwood T.H., Mirza S., Conrad E.U., et al. Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 20 (2002) 3586-3591
7. Bennicelli J.L., and Barr F.G. Chromosomal translocations and sarcomas. Curr Opin Oncol 14 (2002) 412-419
8. Mitelman F. Recurrent chromosome aberrations in cancer. Mutat Res 462 (2000) 247-253
9. Ladanyi M., and Bridge J.A. Contribution of molecular genetic data to the classification of sarcomas. Hum Pathol 31 (2000) 532-538
10. de Alava E., Kawai A., Healey J.H., Fligman I., Meyers P.A., Huvos A.G., et al. EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J Clin Oncol 16 (1998) 1248-1255
11. Ladanyi M., Antonescu C.R., Leung D.H., Woodruff J.M., Kawai A., Healey J.H., et al. Impact of SYT-SSX fusion type on the clinical behavior of synovial sarcoma: a multi-institutional retrospective study of 243 patients. Cancer Res 62 (2002) 135-140
12. Sorensen P.H., Lynch J.C., Qualman S.J., Tirabosco R., Lim J.F., Maurer H.M., et al. PAX3-FKHR and PAX7-FKHR gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group. J Clin Oncol 20 (2002) 2672-2679
13. Zoubek A., Dockhorn-Dworniczak B., Delattre O., Christiansen H., Niggli F., Gatterer-Menz I., et al. Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients?. J Clin Oncol 14 (1996) 1245-1251
14. Barr F.G. Translocations, cancer and the puzzle of specificity. Nat Genet 19 (1998) 121-124
15. van de Rijn M., Barr F.G., Xiong Q.B., Salhany K.E., Fraker D.L., and Fisher C. Radiation-associated synovial sarcoma. Hum Pathol 28 (1997) 1325-1328
16. Olsen R.J., Tarantolo S.R., and Hinrichs S.H. Molecular approaches to sarcoma therapy. Sarcoma 6 (2002) 27-42
17. Rabbitts T.H. Chromosomal translocation master genes, mouse models and experimental therapeutics. Oncogene 20 (2001) 5763-5777
18. Tomescu O., and Barr F.G. Chromosomal translocations in sarcomas: prospects for therapy. Trends Mol Med 7 (2001) 554-559
19. Borden E.C., Baker L.H., Bell R.S., Bramwell V., Demetri G.D., Eisenberg B.L., et al. Soft tissue sarcomas of adults: state of the translational science. Clin Cancer Res 9 (2003) 1941-1956
20. Kawai A., Woodruff J., Healey J.H., Brennan M.F., Antonescu C.R., and Ladanyi M. SYT-SSX gene fusion as a determinant of morphology and prognosis in synovial sarcoma. N Engl J Med 338 (1998) 153-160
21. Rabbitts T.H., Forster A., Larson R., and Nathan P. Fusion of the dominant negative transcription regulator CHOP with a novel gene FUS by translocation t(12;16) in malignant liposarcoma. Nat Genet 4 (1993) 175-180
22. Knezevich S.R., McFadden D.E., Tao W., Lim J.F., and Sorensen P.H. A novel ETV6-NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet 18 (1998) 184-187
23. Knezevich S.R., Garnett M.J., Pysher T.J., Beckwith J.B., Grundy P.E., and Sorensen P.H. ETV6-NTRK3 gene fusions and trisomy 11 establish a histogenetic link between mesoblastic nephroma and congenital fibrosarcoma. Cancer Res 58 (1998) 5046-5048
24. Morrison K.B., Tognon C.E., Garnett M.J., Deal C., and Sorensen P.H. ETV6-NTRK3 transformation requires insulin-like growth factor 1 receptor signaling and is associated with constitutive IRS-1 tyrosine phosphorylation. Oncogene 21 (2002) 5684-5695
25. Martin M.J., Melnyk N., Pollard M., Bowden M., Leong H., Podor T.J., et al. The insulin-like growth factor I receptor is required for Akt activation and suppression of anoikis in cells transformed by the ETV6-NTRK3 chimeric tyrosine kinase. Mol Cell Biol 26 (2006) 1754-1769
26. Park M.S., Lazar A.J., Trent J.C., Conrad C.A., Ludwig J.A., Wang W., et al. Combination therapy with temozolomide and bevacizumab in the treatment of hemangiopericytoma/solitary fibrous tumor: an updated analysis [abstract]. Proc Connective Tissue Oncol Soc 14 (2008) 35064
27. Borden E.C., Amato D.A., Rosenbaum C., Enterline H.T., Shiraki M.J., Creech R.H., et al. Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol 5 (1987) 840-850
28. Maki R.G., Wathen J.K., Patel S.R., Priebat D.A., Okuno S.H., Samuels B., et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of Sarcoma Alliance for Research Through Collaboration study 002. J Clin Oncol 25 (2007) 2755-2763
29. Penel N., Bui B.N., Bay J.O., Cupissol D., Ray-Coquard I., Piperno-Neumann S., et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol 26 (2008) 5269-5274
30. Rosen G., Forscher C., Lowenbraun S., Eilber F., Eckardt J., Holmes C., et al. Synovial sarcoma. Uniform response of metastases to high dose ifosfamide. Cancer 73 (1994) 2506-2511
31. Garcia-Carbonero R., Supko J.G., Maki R.G., Manola J., Ryan D.P., Harmon D., et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol 23 (2005) 5484-5492
32. Garcia-Carbonero R., Supko J.G., Manola J., Seiden M.V., Harmon D., Ryan D.P., et al. Phase II and pharmacokinetic study of ecteinascidin 743 in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol 22 (2004) 1480-1490
33. Grosso F., Jones R.L., Demetri G.D., Judson I.R., Blay J.Y., Le Cesne A., et al. Efficacy of trabectedin (ecteinascidin-743) in advanced pretreated myxoid liposarcomas: a retrospective study. Lancet Oncol 8 (2007) 595-602
34. Meazza C., Casanova M., Zaffignani E., Luksch R., Podda M., Favini F., et al. Efficacy of topotecan plus vincristine and doxorubicin in children with recurrent/refractory rhabdomyosarcoma. Med Oncol 26 (2009) 67-72
35. Hansmann A., Adolph C., Vogel T., Unger A., and Moeslein G. High-dose tamoxifen and sulindac as first-line treatment for desmoid tumors. Cancer 100 (2004) 612-620
36. Gadducci A., Cosio S., Romanini A., and Genazzani A.R. The management of patients with uterine sarcoma: a debated clinical challenge. Crit Rev Oncol Hematol 65 (2008) 129-142
37. Heinrich M.C., McArthur G.A., Demetri G.D., Joensuu H., Bono P., Herrmann R., et al. Clinical and molecular studies of the effect of imatinib on advanced aggressive fibromatosis (desmoid tumor). J Clin Oncol 24 (2006) 1195-1203
38. D'Adamo D.R., Anderson S.E., Albritton K., Yamada J., Riedel E., Scheu K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol 23 (2005) 7135-7142
39. Wunder J.S., Nielsen T.O., Maki R.G., O'Sullivan B., and Alman B.A. Opportunities for improving the therapeutic ratio for patients with sarcoma. Lancet Oncol 8 (2007) 513-524
40. Mita M.M., Mita A.C., Chu Q.S., Rowinsky E.K., Fetterly G.J., Goldston M., et al. Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies. J Clin Oncol 26 (2008) 361-367
41. Sarcoma Meta-Analysis Collaboration. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350 (1997) 1647-1654
42. Frustaci S., Gherlinzoni F., De Paoli A., Bonetti M., Azzarelli A., Comandone A., et al. Adjuvant chemotherapy for adult soft tissue sarcomas of the extremities and girdles: results of the Italian randomized cooperative trial. J Clin Oncol 19 (2001) 1238-1247
43. Frustaci S., De Paoli A., Bidoli E., La Mura N., Berretta M., Buonadonna A., et al. Ifosfamide in the adjuvant therapy of soft tissue sarcomas. Oncology 65 Suppl 2 (2003) 80-84
44. Woll P.J., Van Glabbeke M., Hohenberger P., Le Cesne A., Gronchi A., Hoekstra H.J., et al. Adjuvant chemotherapy with doxorubicin and ifosfamide in resected soft tissue sarcoma: interim analysis of a randomised phase III trial [abstract]. J Clin Oncol 25 (2007) 10008
45. Pervaiz N., Colterjohn N., Farrokhyar F., Tozer R., Figueredo A., and Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer 113 (2008) 573-581
46. Pinedo H.M., Vendrik C.P., Bramwell V.H., van Slooten E.A., Deakin D.P., van Unnik J.A., et al. Evaluation of adjuvant therapy in soft tissue sarcoma. A collaborative multidisciplinary approach. EORTC protocol 62771. Eur J Cancer 15 (1979) 811-820
47. Le Cesne A., Van Glabbeke M., Woll P.J., Bramwell V.H., Casali P.G., Hoekstra H.J., et al. The end of adjuvant chemotherapy era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma: pooled analysis of the two STBSG-EORTC phase III clinical trials [abstract]. J Clin Oncol 26 (2008) 10525
48. Schöffski P., Casali P.G., Taron M., Van Oosterom A.T., Judson I.R., Grosso F., et al. DNA repair functionality modulates the clinical outcome of patients with advanced sarcoma treated with trabectedin (ET-743) [abstract]. J Clin Oncol 24 (2006) 9522
49. Gortzak E., Azzarelli A., Buesa J., Bramwell V.H., van Coevorden F., van Geel A.N., et al. A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37 (2001) 1096-1103
50. Lorigan P., Verweij J., Papai Z., Rodenhuis S., Le Cesne A., Leahy M.G., et al. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 25 (2007) 3144-3150
51. Wust P., Hildebrandt B., Sreenivasa G., et al. Hyperthermia in combined treatment of cancer. Lancet Oncol 3 (2002) 487-497
52. Milani V., and Noessner E. Effects of thermal stress on tumor antigenicity and recognition by immune effector cells. Cancer Immunol Immunother 55 (2006) 312-319
53. Wust P., Cho C.H., Hildebrandt B., et al. Thermal monitoring: Invasive, minimal-invasive and non-invasive approaches. Int J Hyperthermia 22 (2006) 255-262
54. Gellermann J., Hildebrandt B., Issels R., Ganter H., Wlodarczyk W., Budach V., et al. Noninvasive magnetic resonance thermography of soft tissue sarcomas during regional hyperthermia: correlation with response and direct thermometry. Cancer 107 (2006) 1373-1382
55. Issels R.D., Bosse D., Abdel-Rahman S., et al. Preoperative systemic etoposide/ifosfamide/doxorubicin chemotherapy combined with regional hyperthermia in high-risk sarcoma: a pilot study. Cancer Chemother Pharmacol 31 Suppl 2 (1993) S233-S237
56. Issels R.D., Abdel-Rahman S., Wendtner C.M., et al. Neoadjuvant chemotherapy combined with regional hyperthermia (RHT) for locally advanced primary or recurrent high-risk adult soft-tissue sarcomas (STS) of adults: long-term results of a phase II study. Eur J Cancer 37 (2001) 1599-08
57. Wendtner C.M., Abdel-Rahman S., Krych M., et al. Response to neoadjuvant chemotherapy combined with regional hyperthermia predicts long-term survival for adult patients with retroperitoneal and visceral high-risk soft tissue sarcomas. J Clin Oncol 20 (2002) 3156-3164
58. Multhoff G., Botzler C., Jennen L., et al. Heat shock protein 72 on tumor cells. A recognition structure for natural killer cells. J Immunol 158 (1997) 4341-4350
59. Dewey W.C. Arrhenius relationships from the molecule and cell to the clinic. Int J Hyperthermia 10 (1994) 457-483
60. Issels R.D., Lindner L.H., Wust P., et al. Regional hyperthermia (RHT) improves response and survival when combined with systemic chemotherapy in the management of locally advanced, high grade soft tissue sarcomas (STS) of the extremities, the body wall and the abdomen: A phase III randomised prospective trial (EORTC-ESHO intergroup trial). J Clin Oncol 25 18S (2007) 10009
61. Lindner L., Mella O., Kuhlencordt M., et al. Early progression in patients with high-risk soft tissue sarcomas (STS): a phase III randomized prospective trial (EORTC/ESHO intergroup trial) of neoadjuvant chemotherapy with or without regional hyperthermia (RHT) [abstract 7504]. Eur J Cancer 5 Suppl 4 (2007) 403
62. Issels R.D. Regional hyperthermia in high-risk soft tissue sarcomas. Curr Opin Oncol 20 (2008) 438-443